Obesogens

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 17, Issue 5, 2010, Pages 453-459

  Grün, Felix ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

endocrine disruptors; nuclear hormone receptors; obesogen; organotins; phthalates

Indexed keywords

CELL NUCLEUS RECEPTOR; CHEMICAL COMPOUND; OBESOGEN; ORGANOTIN COMPOUND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; RETINOID X RECEPTOR; UNCLASSIFIED DRUG;

ADIPOGENESIS; CRYSTAL STRUCTURE; ENVIRONMENTAL EXPOSURE; HUMAN; METABOLIC SYNDROME X; NONHUMAN; OBESITY; REVIEW; WHITE ADIPOSE TISSUE;

ADIPOCYTES; ADIPOSE TISSUE; ANIMALS; APPETITE REGULATION; ENDOCRINE DISRUPTORS; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL POLLUTANTS; FEMALE; FLUOROCARBONS; HALOGENATED DIPHENYL ETHERS; HOMEOSTASIS; HUMANS; MALE; MICE; OBESITY; PHENOLS; PHENOTYPE; PHTHALIC ACIDS; PPAR GAMMA; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RETINOID X RECEPTORS; TRANSCRIPTION, GENETIC; TRIALKYLTIN COMPOUNDS;

EID: 77956266490     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e32833ddea0     Document Type: Review

References (86)

1. Heindel JJ, vom Saal FS. Role of nutrition and environmental endocrine disrupting chemicals during the perinatal period on the aetiology of obesity. Mol Cell Endocrinol 2009; 304:90-96.
2. Schwitzgebel VM, Somm E, Klee P. Modeling intrauterine growth retardation in rodents: impact on pancreas development and glucose homeostasis. Mol Cell Endocrinol 2009; 304:78-83.
3. Somm E, Schwitzgebel VM, Vauthay DM, et al. Prenatal nicotine exposure alters early pancreatic islet and adipose tissue development with consequences on the control of body weight and glucose metabolism later in life. Endocrinology 2008; 149:6289-6299.
4. Avram MM, Avram AS, James WD. Subcutaneous fat in normal and diseased states 3. Adipogenesis: from stem cell to fat cell. J Am Acad Dermatol 2007; 56:472-492.
5. Spalding KL, Arner E, Westermark PO, et al. Dynamics of fat cell turnover in humans. Nature 2008; 453:783-787.
6. Jo J, Gavrilova O, Pack S, et al. Hypertrophy and/or hyperplasia: dynamics of adipose tissue growth. PLoS Comput Biol 2009; 5:e1000324.
7. Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, et al. Endocrine-dis-rupting chemicals: an Endocrine Society scientific statement. Endocr Rev 2009; 30:293-342.
8. Thornton JW. Nonmammalian nuclear receptors: evolution and endocrine disruption. Pure Appl Chem 2003; 75 (11-12):1827-1839.
9. Thornton JW, Need E, Crews D. Resurrecting the ancestral steroid receptor: ancient origin of estrogen signaling. Science 2003; 301:1714-1717.
10. Yadav N, Cheng D, Richard S, et al. CARM1 promotes adipocyte differentiation by coactivating PPARgamma. EMBO Rep 2008; 9:193-198.
11. Lee J, Saha PK, Yang QH, et al. Targeted inactivation of MLL3 histone H3-Lys-4 methyltransferase activity in the mouse reveals vital roles for MLL3 in adipogenesis. Proc Natl Acad Sci USA 2008; 105:19229-19234.
12. Grun F, Blumberg B. Perturbed nuclear receptor signaling by environmental obesogens as emerging factors in the obesity crisis. Rev Endocrine Metab Disord 2007; 8:161-171.
13. Rosen ED, Sarraf P, Troy AE, et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 1999; 4:611-617.
14. Argmann CA, Cock TA, Auwerx J. Peroxisome proliferator-activated receptor gamma: the more the merrier? Eur J Clin Invest 2005; 35:82-92; discussion 80.
15. Rieusset J, Touri F, Michalik L, et al. A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity. Molec Endocrinol (Baltimore, Md) 2002; 16:2628-2644.
16. Nakano R, Kurosaki E, Yoshida S, et al. Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivo. Biochem Pharmacol 2006; 72:42-52.
17. Imai T, Jiang M, Chambon P, Metzger D. Impaired adipogenesis and lipolysis in the mouse upon selective ablation of the retinoid X receptor alpha mediated byatamoxifen-induciblechimericCre recombinase (Cre-ERT2) in adipocytes. Proc Natl Acad Sci USA 2001; 98:224-228.
18. Metzger D, Imai T, Jiang M, et al. Functional role of RXRs and PPARgamma in mature adipocytes. Prostaglandins Leukot Essent Fatty Acids 2005; 73:51-58.
19. Larsen TM, Toubro S, Astrup A. PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? Int J Obes Relat Metab Disord 2003; 27:147-161.
20. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, orglyburide monotherapy. N Engl J Med 2006; 355:2427-2443.
21. Kanayama T, Kobayashi N, Mamiya S, et al. Organotin compounds promote adipocyte differentiation as agonists of the peroxisome proliferator-activated receptor gamma/retinoid X receptor pathway. Molec Pharmacol 2005; 67:766-774.
22. Grun F, Watanabe H, Zamanian Z, et al. Endocrine-disrupting organotin compounds are potent inducers of adipogenesis in vertebrates. Molec Endocrinol (Baltimore, Md) 2006; 20:2141-2155.
23. Itoh T, Fairall L, Amin K, et al. Structural basis for the activation of PPARgamma by oxidized fatty acids. Nat Struct Mol Biol 2008; 15:924-931.
24. Buck BA, Mascioni A, Cramer CJ, Veglia G. Interactions of alkyltin salts with biological dithiols: dealkylation and induction of a regular beta-turn structure in peptides. J Am Chem Soc 2004; 126:14400-14410.
25. Lo S, Allera A, Albers P, et al. Dithioerythritol (DTE) prevents inhibitory effects of triphenyltin (TPT) on the key enzymes of the human sex steroid hormone metabolism. J Steroid Biochem Molec Biol 2003; 84:569-576.
26. Grun F, Blumberg B, editors. Environmental obesogens: organotins and endocrine disruption of RXR:PPARy signaling in adipogenesis. FASEB Summer Research Conference: Retinoids; 2006; Indian Wells, CA: FASEB.
27. Le Maire A, Grimaldi M, Roecklin D, et al. Activation of RXR-PPAR hetero dimers by organotin environmental endocrine disruptors. EMBO Rep 2009; 10:367-373.
28. Maire A, Bourguet W, Balaguer P. A structural view of nuclear hormone receptor: endocrine disruptor interactions. Cell Mol Life Sci 2010; 67:1219-1237.
29. Elbrecht A, Chen Y, Adams A, et al. L-764406 is a partial agonist of human peroxisome proliferator-activated receptor gamma. The role of Cys313 in ligand binding. J Biol Chem 1999; 274:7913-7922.
30. Leesnitzer LM, Parks DJ, Bledsoe RK, et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 2002; 41:6640-6650.
31. Waku T, Shiraki T, Oyama T, et al. Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids. J Molec Biol 2009; 385:188-199.
32. Gumy C, Chandsawangbhuwana C, Dzyakanchuk AA, et al. Dibutyltin disrupts glucocorticoid receptor function and impairs glucocorticoid-induced suppression of cytokine production. PLoS One 2008; 3:e3545.
33. Atanasov AG, Nashev LG, Tam S, et al. Organotins disrupt the 11beta-hydroxysteroid dehydrogenase type 2-dependent local inactivation of glucocorticoids. Environ Health Perspect 2005; 113:1600-1606.
34. Sargis RM, Johnson DN, Choudhury RA, Brady MJ. Environmental endocrine disruptors promote adipogenesis in the 3T3-L1 cell line through glucocorti coid receptor activation. Obesity (Silver Spring, Md.) 2009; 18:1283-1288.
35. Inadera H, Shimomura A. Environmental chemical tributyltin augments adipocyte differentiation. Toxicol Lett 2005; 159:226-234.
36. Zuo Z, Chen S, Wu T, et al. Tributyltin causes obesity and hepatic steatosis in male mice. Environ Toxicol 2009; doi: 10.1002/tox.20531.
37. Smith BS. Male characteristics on female mud snails caused by antifouling bottom paints. J Appl Toxicol 1981; 1:22-25.
38. Horiguchi T. Masculinization of female gastropod mollusks induced by organotin compounds, focusing on mechanism of actions of tributyltin and triphenyltin for development of imposex. Environ Sci 2006; 13:77-87.
39. Le Curieux-Belfond O, Moslemi S, Mathieu M, Seralini GE. Androgen metabolism in oyster Crassostrea gigas: evidence for 17beta-HSD activities and characterization of an aromatase-like activity inhibited by pharmacological compounds and a marine pollutant. J Steroid Biochem Molec Biol 2001; 78:359-366.
40. Santos MM, ten Hallers-Tjabbes CC, Vieira N, et al. Cytochrome P450 differences in normal and imposex-affected female whelk Buccinum undatum from the open North Sea. Marine Environ Res 2002; 54 (3-5):661-665.
41. Lavado R, Sugni M, Candia Carnevali MD, Porte C. Triphenyltin alters androgen metabolism in the sea urchin Paracentrotus lividus. Aquatic Toxicol (Amsterdam, Netherlands) 2006; 79:247-256.
42. Heidrich DD, Steckelbroeck S, Klingmuller D. Inhibition of human cytochrome P450 aromatase activity by butyltins. Steroids 2001; 66:763-769.
43. Saitoh M, Yanase T, Morinaga H, et al. Tributyltin or triphenyltin inhibits aromatase activity in the human granulosa-like tumor cell line KGN. Biochem Biophys Res Commun 2001; 289:198-204.
44. Cooke GM. Effect of organotins on human aromatase activity in vitro. Toxicol Lett 2002; 126:121-130.
45. Mu YM, Yanase T, Nishi Y, et al. Combined treatment with specific ligandsfor PPARgamma:RXR nuclear receptor system markedly inhibits the expression of cytochrome P450arom in human granulosa cancer cells. Mol Cell Endocrinol 2001; 181 (1-2):239-248.
46. Nishikawa J, Mamiya S, Kanayama T, et al. Involvement of the retinoid X receptor in the development of imposex caused by organotins in gastropods. Environ Sci Technol 2004; 38:6271-6276.
47. Castro LF, Lima D, Machado A, et al. Imposex induction is mediated through the retinoid X receptor signalling pathway in the neogastropod Nucella lapillus. Aquatic Toxicol (Amsterdam, Netherlands) 2007; 85:57-66.
48. Lyssimachou A, Navarro JC, Bachmann J, Porte C. Triphenyltin alters lipid homeostasis in females of the ramshorn snail Marisa cornuarietis. Environ Pollut 2009; 157:1714-1720.
49. Janer G, Navarro JC, Porte C. Exposure to TBT increases accumulation of lipids and alters fatty acid homeostasis in the ramshorn snail Marisa cornuarietis. Comp Biochem Physiol C Toxicol Pharmacol 2007; 146:368-374.
50. Wadhwa PD, Buss C, Entringer S, Swanson JM. Developmental origins of health and disease: brief history of the approach and current focus on epigenetic mechanisms. Semin Reprod Med 2009; 27:358-368.
51. Noer A, Lindeman LC, Collas P. Histone H3 modifications associated with differentiation and long-term culture of mesenchymal adipose stem cells. Stem Cells Dev 2009; 18:725-736.
52. Szyf M, Weaver IC, Champagne FA, et al. Maternal programming of steroid receptor expression and phenotype through DNA methylation in the rat. Front Neuroendocrinol 2005; 26:139-162.
53. Lillycrop KA, Slater-Jefferies JL, Hanson MA, et al. Induction of altered epigenetic regulation of the hepatic glucocorticoid receptor in the offspring of rats fed a protein-restricted diet during pregnancy suggests that reduced DNA methyltransferase-1 expression is involved in impaired DNA methylation and changes in histone modifications. Br J Nutr 2007; 97:1064-1 073.
54. Rees WD, McNeil CJ, Maloney CA. The roles of PPARs in the fetal origins of metabolic health and disease. PPAR Res 2008; 2008:459030.
55. Carfi M, Croera C, Ferrario D, et al. TBTC induces adipocyte differentiation in human bone marrow long term culture. Toxicology 2008; 249:11-18.
56. Kirchner S, Kieu T, Chow C, et al. Prenatal exposure to the environmental obesogen tributyltin predisposes multipotent stem cells to become adipocytes. Molec Endocrinol (Baltimore, Md) 2010; 24:526-539.
57. Wang Y, Wang C, Zhang J, et al. DNA hypomethylation induced by tributyltin, triphenyltin, and a mixture of these in Sebastiscus marmoratus liver. Aquatic Toxicol (Amsterdam, Netherlands) 2009; 95:93-98.
58. Osada S, Nishikawa J, Nakanishi T, et al. Some organotin compounds enhance histone acetyltransferase activity. Toxicol Lett 2005; 155:329-335.
59. Hatch EE, Nelson JW, Stahlhut RW, Webster TF. Association of endocrine disruptorsand obesity: perspectives from epidemiological studies. Int J Androl 2010; 33:324-332.
60. Antizar-Ladislao B. Environmental levels, toxicity and human exposure to tributyltin (TBT)-contaminated marine environment. A review. b-antizar@hot-mail.com. Environ Int 2008; 34:292-308.
61. Kannan K, Senthilkumar K, Giesy J. Occurrence of butyltin compounds in human blood. Environ Sci Tech 1999; 33:1776-1779.
62. Takahashi S, Mukai H, Tanabe S, et al. Butyltin residues in livers of humans and wild terrestrial mammals and in plastic products. Environ Pollut 1999; 106:213-218.
63. Rantakokko P, Turunen A, Verkasalo PK, et al. Blood levels of organotin compounds and their relation to fish consumption in Finland. Sci Total Environ 2008; 399:90-95.
64. Vandenberg LN, Maffini MV, Sonnenschein C, et al. Bisphenol-A and the great divide: a review of controversies in the field of endocrine disruption. Endocr Rev 2009; 30:75-95.
65. NTP-CERHR Monograph on the Potential Human Reproductive and Developmental Effects of Bisphenol A. NTP CERHR MON 2008; Sep:i-III1.
66. Rubin BS, Murray MK, Damassa DA, et al. Perinatal exposure to low doses of bisphenol A affects body weight, patterns of estrous cyclicity, and plasma LH levels. Environ Health Perspect 2001; 109:675-680.
67. Miyawaki J, Sakayama K, Kato H, et al. Perinatal and postnatal exposure to bisphenol a increases adipose tissue mass and serum cholesterol level in mice. J Atheroscler Thromb 2007; 14:245-252.
68. Somm E, Schwitzgebel VM,Toulotte A, et al. Perinatal exposure to bisphenol a alters early adipogenesis in the rat. Environ Health Perspect 2009; 117:1549-1555.
69. Ryan KK, Haller AM, Sorrell JE, et al. Perinatal exposure to bisphenol-aand the development of metabolic syndrome in CD-1 mice. Endocrinology 2010; 151:2603-2612.
70. Hugo ER, Brandebourg TD, Woo JG, et al. Bisphenol A at environmentally relevant doses inhibits adiponectin release from human adipose tissue ex-plants and adipocytes. Environ Health Perspect 2008; 116:1642-1647.
71. Ben-Jonathan N, Hugo ER, Brandebourg TD. Effects of bisphenol A on adipokine release from human adipose tissue: implications for the metabolic syndrome. Mol Cell Endocrinol 2009; 304 (1-2):49-54.
72. Lang IA, Galloway TS, Scarlett A, et al. Association of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults. J Am Med Assoc 2008; 300:1303-1310.
73. Wittassek M, Wiesmuller GA, Koch HM, et al. Internal phthalate exposure over the last two decades-a retrospective human biomonitoring study. Int J Hygiene Environ Health 2007; 210:319-333.
74. Wittassek M, Angerer J, Kolossa-Gehring M, et al. Fetal exposure to phthalates: a pilot study. Int J Hygiene Environ Health 2009; 212:492-498.
75. Boberg J, Metzdorff S, Wortziger R, et al. Impact of diisobutyl phthalate and other PPAR agonists on steroidogenesis and plasma insulin and leptin levels in fetal rats. Toxicology 2008; 250:75-81.
76. Feige JN, Gelman L, Rossi D, et al. The endocrine disruptor monoethyl-hexyl-phthalate is a selective peroxisome proliferator-activated receptor gamma modulator that promotes adipogenesis. J Biol Chem 2007; 282:19152-19166.
77. Shen O, Du G, Sun H, et al. Comparison of in vitro hormone activities of selected phthalates using reporter gene assays. Toxicol Lett 2009; 191:9-14.
78. Stahlhut RW, van Wijgaarden E, Dye TD, et al. Concentrations of urinary phthalate metabolites are associated with increased waist circumferece and insulin resistance in adult U.S. males. Environ Health Perspect 2007; 115:876-882.
79. Hatch EE, Nelson JW, Qureshi MM, et al. Association of urinary phthalate metabolite concentrations with body mass index and waist circumference: a cross-sectional study of NHANES data, 1999-2002. Environ Health 2008; 7:27.
80. Vanden Heuvel JP, Thompson JT, Frame SR, Gillies PJ. Differential activation of nuclear receptors by perfluorinated fatty acid analogs and natural fatty acids: a comparison of human, mouse, and rat peroxisome proliferator-activated receptor-alpha,-beta, and-gamma, liver X receptor-beta, and retinoid X receptor-alpha. Toxicol Sci 2006; 92:476-489.
81. Olsen GW, Burris JM, Ehresman DJ, et al. Half-life of serum elimination of perfluorooctanesulfonate,perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ Health Perspect 2007; 115:1298-1305.
82. Fei C, McLaughlin JK, Tarone RE, Olsen J. Perfluorinated chemicals and fetal growth: a study within the Danish National Birth Cohort. Environ Health Perspect 2007; 115:1677-1682.
83. Fei C, McLaughlin JK, Tarone RE, Olsen J. Fetal growth indicators and perfluorinated chemicals: a study in the Danish National Birth Cohort. Am J Epidemiol 2008; 168:66-72.
84. Zoeller TR. Environmental chemicals targeting thyroid. Hormones (Athens) 2010; 9:28-40.
85. Knudsen N, Laurberg P, Rasmussen LB, et al. Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. J Clin Endocrinol Metab 2005; 90:4019-4024.
86. Baillie-Hamilton PF. Chemical toxins: a hypothesis to explain the global obesity epidemic. J Altern Complement Med 2002; 8:185-192.